Optimal Prognostic Threshold for Acute Myeloid Leukemia (AML) Measurable Residual Disease (MRD) Positivity By Multiparameter Flow Cytometry: A Report of 2,051 Patients from MRC/NCRI, Gimema, HOVON, and Seattle

The ELN MRD Working Party defines multiparameter flow cytometry (MFC)-based measurable residual disease (MRD) positivity for AML at the threshold of ≥0.1% of CD45-expressing cells with the target immunophenotype. This assay-agnostic approach has not been empirically validated.

https://www.astctjournal.org/article/S2666-6367(23)01765-7/fulltext?rss=yes

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Eduardo Rodr íguez-Arbolí, Megan Othus, Sylvie Freeman, Francesco Buccisano, Lok Lam Ngai, Ian Thomas, Raffaele Palmieri, Jacqueline Cloos, Sean Johnson, Elisa Meddi, Nigel H. Russell, Adriano Venditti, Patrycja Gradowska, Gert J. Ossenkoppele, Bob Lowe Tags: 11 Source Type: research